A randomized controlled trial tells you that, on average, intervention X works for population Y. It does not tell you whether X will work for you specifically. This distinction is not pedantic. Effect sizes in lifestyle and supplement trials are typically reported as means with confidence intervals around a population — and almost always, the individual responses inside that population include people who got nothing from the intervention and people who got much more than the average. The methodology that resolves this is called an N=1 trial, also written n-of-1. It has a 70-year history in clinical research, a real statistical framework, and a small but growing presence in chronic disease management. Almost no consumer health app implements it properly. This article walks through what N=1 trials are, why they are the right tool for personal health decisions, what the methodology looks like in practice, and what changes when you actually run one.
The problem with applying RCT results to yourself
Consider a real example. A 12-week randomized trial of magnesium supplementation in 100 adults reports a mean improvement of 7 minutes in objective sleep onset latency, with a 95 percent confidence interval of 2 to 12 minutes. This is a real, modest, statistically significant population effect. What it does not tell you: of those 100 adults, perhaps 30 had a meaningful response of 15 minutes or more, 50 had a small response of zero to 7 minutes, and 20 had no response or a slight worsening. The average over the cohort is the 7-minute number.
If you take the supplement based on the trial result, you are buying a lottery ticket on which of those three groups you fall into. The trial gives you the prior probability of being a responder. It cannot tell you whether you actually are one.
This is fine for population-level decisions about drug approval, public health policy, and clinical guidelines. It is the wrong epistemology for individual decision-making about lifestyle interventions, where the variance across individuals is often as large as or larger than the mean effect. Senn (Annals of Internal Medicine, 2018) made this argument formally: for many chronic-disease interventions, individual response variation is the dominant source of uncertainty, and population means systematically mislead individual choice.
What an N=1 trial is
An N=1 trial is a within-subject controlled experiment. The single subject is both the treatment group and the control group, tested across multiple intervention and baseline periods. The framework was developed in the 1970s and 1980s for chronic conditions where between-subject variation made traditional RCTs uninformative for any individual patient. Guyatt and colleagues at McMaster formalized the modern version (Annals of Internal Medicine, 1986) as a way to run controlled trials of an individual patient's therapy.
The core design has four components.
Baseline. A defined period (typically 1 to 4 weeks) during which the outcome of interest is measured repeatedly under normal conditions, with no intervention. This establishes your personal reference distribution: not just the mean of your outcome, but the natural day-to-day variability.
Intervention. A defined period (typically 2 to 8 weeks, long enough for the intervention to produce a steady-state effect) during which the intervention is applied consistently and the outcome continues to be measured.
Washout. A defined period (typically 1 to 4 weeks) during which the intervention is removed and the outcome is measured. This tests whether removing the intervention returns the outcome to baseline, which is critical evidence that the intervention is responsible for any observed change.
Replication. A second intervention period followed by a second washout, ideally with the order of intervention and control randomized. Replication is what distinguishes a real causal inference from a coincidence.
The full design — baseline, intervention 1, washout 1, intervention 2, washout 2 — produces enough within-subject contrast to estimate whether the intervention worked for this specific person, with quantifiable uncertainty. Lillie et al. (Personalized Medicine, 2011) provide a comprehensive review of the methodology and its modern applications, including in chronic pain, ADHD medication titration, and supplement evaluation.
The statistics, in brief
You do not need a population to make a causal inference. You need enough within-subject measurements during baseline and intervention to distinguish the intervention effect from your natural variability.
The simplest analysis: compare the mean of the outcome during intervention periods to the mean during baseline and washout periods. If the difference exceeds two standard deviations of the baseline distribution, the effect is meaningful at roughly the 95 percent confidence level for an individual. This is the same logic as a z-test, applied within rather than between subjects.
More sophisticated analyses use interrupted time series models or Bayesian frameworks that account for the temporal structure of repeated measurements (Senn, Statistics in Medicine, 2018). These models can distinguish slow drift from intervention effects and can quantify the probability that an observed change is causal rather than coincidental.
The key insight: the statistical power of an N=1 trial depends on the ratio of intervention effect size to within-subject variability, not on sample size. If the intervention produces a large effect relative to your natural day-to-day variation, you can detect it in two cycles. If the effect is small relative to your variation, you may need many cycles or a longer baseline.
This is why baseline length matters so much. A two-week baseline gives you 14 data points to estimate your natural variability. A four-week baseline gives 28, which dramatically tightens the noise estimate and lets you detect smaller intervention effects.
Why no consumer app does this properly
The methodology has been understood for 40 years. The statistical framework is well-developed. Wearable devices generate the dense, continuous outcome data N=1 trials require. And almost no consumer health app implements the design.
The structural reasons are easy to identify.
The product needs to deliver value immediately. A real N=1 trial requires a two- to four-week baseline during which the app tells you nothing definitive. Onboarding metrics suffer. Companies optimize for an experience where the user starts seeing scores and recommendations on day one, which means the recommendations are based on population means rather than personal experiments.
The user has to commit to a controlled intervention. Real protocols require that during the intervention period, the user changes only the variable being tested and keeps everything else constant. This is hard. People want to test five things at once and figure out which one worked. The five-things-at-once experiment is not interpretable.
The user has to tolerate a washout. This is the hardest sell. If an intervention seems to be working, the natural impulse is to keep doing it, not remove it and see whether the effect persists. Yet without the washout and the replication, you cannot distinguish a real effect from a coincidence with seasonal variation, a placebo response, or a confounding behavioral change.
The technical infrastructure is non-trivial. Properly implementing N=1 trials at scale requires per-user trial state management, randomization of intervention order, automated outcome computation, statistical inference, and an interpretation layer that explains the result honestly (including the case where the trial is inconclusive). Most apps would rather ship a simple recommendation engine that always produces a confident-sounding answer.
What an N=1 trial looks like in practice
Take a concrete example: testing whether magnesium glycinate at 300 mg before bed improves your sleep onset latency.
Pre-trial planning. Define the outcome (sleep onset latency, measured by your wearable). Define the unit (minutes). Define what counts as a meaningful change (you might decide a 5-minute improvement is the smallest worthwhile difference). Define how many cycles you will run (typically two intervention/washout pairs).
Baseline (weeks 1-3). No magnesium. Measure sleep onset latency every night. Keep everything else as constant as possible: same bedtime, no major travel, no new caffeine habits, no other new supplements. After three weeks, you have 21 nights of baseline data with a personal mean and standard deviation.
Intervention 1 (weeks 4-7). Magnesium 300 mg, 30 minutes before bed, every night. Continue measuring. Keep all other variables constant. After four weeks, you have 28 nights of intervention data.
Washout 1 (weeks 8-10). Stop magnesium. Continue measuring. After three weeks, you have 21 nights of washout data, which should ideally return to your baseline distribution if the magnesium was working.
Intervention 2 (weeks 11-14). Resume magnesium. Continue measuring.
Washout 2 (weeks 15-17). Stop magnesium. Continue measuring.
Analysis. Compare the mean of the two intervention periods to the mean of the baseline and two washout periods. If the difference is at least 5 minutes and exceeds two standard deviations of your baseline distribution, you have credible evidence that magnesium works for you. If the difference is smaller or inconsistent across the two intervention cycles, you have credible evidence that it does not — at least not at this dose, in this form, on this schedule.
The whole trial takes 17 weeks. That is a fair amount of patience, but the alternative is years of taking a supplement that may or may not be doing anything.
What changes when you start running them
Two things change for almost everyone who runs even a handful of N=1 trials with this rigor.
First, the number of interventions that survive your personal testing is much smaller than the number recommended by the consumer health information environment. Most things that are supposed to work either do not work for you, or work so weakly that the effect is inside your noise band. This is the honest individual-level result of the same statistical heterogeneity that population RCTs hide.
Second, the things that do survive testing produce real, replicable, attributable effects. You stop being uncertain about whether they are working. You stop debating yourself about whether to continue. The protocol becomes durable because the evidence is yours, not someone else's mean.
The N=1 framework also changes how you read population research. Trial results stop being instructions and become priors — they tell you what is worth testing, with what probability of working, not what to do.
Where N=1 trials are most valuable
The methodology is best suited to interventions with the following properties: outcomes that can be measured frequently (daily or near-daily), interventions with effects on a timescale of days to weeks (not years), reversible interventions (so a washout is meaningful), and interventions where individual variation in response is known or suspected to be high.
Sleep interventions, supplements, dietary changes, exercise scheduling, and most behavioral interventions fit. Major surgery and many pharmaceutical interventions do not, either because the outcomes take too long to manifest, the intervention is irreversible, or both. Statin therapy, for instance, is a poor N=1 candidate because the cardiovascular outcome is measured in years rather than weeks. ApoB response to statins, however, is an excellent N=1 outcome — you can measure ApoB at baseline, on therapy, and after a brief drug holiday under medical supervision.
Key takeaways
- RCT results are population means. They tell you the prior probability that an intervention works, not whether it works for you.
- N=1 trials are within-subject controlled experiments with a 70-year history in clinical research. They are the right epistemology for individual decision-making about lifestyle interventions.
- The minimum viable design is baseline, intervention, washout, intervention, washout, with consistent outcome measurement throughout. Two intervention/washout pairs distinguish real effects from coincidence.
- Statistical power depends on the ratio of effect size to within-subject variability, not on sample size. A longer baseline tightens your noise estimate and lets you detect smaller effects.
- Most consumer health apps do not implement N=1 trials because the methodology requires patience, commitment to controlled testing, and tolerance for inconclusive results, all of which hurt onboarding and retention metrics.
Sources
1. Guyatt G, et al. Determining optimal therapy: randomized trials in individual patients. NEJM. 1986;314(14):889-892. 2. Senn S. Mastering variation: variance components and personalised medicine. Statistics in Medicine. 2016;35(7):966-977. 3. Senn S. Statistical pitfalls of personalized medicine. Nature. 2018;563:619-621. 4. Lillie EO, et al. The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?. Personalized Medicine. 2011;8(2):161-173. 5. Kravitz RL, et al. Design and implementation of n-of-1 trials: a user's guide. AHRQ Publication No. 13(14)-EHC122-EF. 2014. 6. Mirza RD, et al. The history and development of N-of-1 trials. Journal of the Royal Society of Medicine. 2017;110(8):330-340. 7. Davidson KW, et al. N-of-1 randomized trials in clinical care. JAMA. 2021;326(15):1525-1526.
---
Want VITA to do this for you automatically? Join the waitlist